- Home
- Human regulatory
- Marketing authorisation
The European Medicines Agency (EMA) is responsible for the scientific evaluation of centralised marketing authorisation applications (MAA). Once granted by the European Commission, the centralised marketing authorisation is valid in all European Union (EU) Member States, Iceland, Norway and Liechtenstein.
United Kingdom’s (UK) withdrawal from the EU
EMA has published important information to help users of the centralised procedure prepare for the expected consequences of 'Brexit', including their obligations related to establishment within the European Economic Area (EEA). For more information, see UK’s withdrawal from the EU.
In this section
General requirements for all applications | Particular application types |
---|---|
Steps involved in obtaining an EU marketing authorisation
Submission of eligibility request |
---|
18 to 7 months before submission of marketing authorisation application (MAA) |
To find out whether a product can be evaluated under the centralised procedure, applicants should always submit an eligibility request using the specific form and accompanied by a justification.
More information: pre-authorisation guidance - section 2: Steps prior to submitting the application |

Notification of intention to submit an application |
---|
7 months before submission of MAA |
Applicants should consider the date of submission carefully, referring to the published submission dates and the guidance below:
To notify the Agency of the intended submission date, they should email the pre-submission request form (intent to submit MA) to pa-bus@ema.europa.eu. The selected scope of request should be: 'Centralised Procedure – Intent to submit a MAA'.
More information: pre-authorisation guidance – section 2: Steps prior to submitting the application |

Appointment of rapporteurs |
---|
7 months before submission of MAA |
The Committee for Medicinal Products for Human Use (CHMP) and the Pharmacovigilance Risk Assessment Committee (PRAC) appoints (co-)rapporteurs to conduct the scientific assessment.
For advanced therapy medicinal products, (co-)rapporteurs are also appointed from members of the Committee for Advanced Therapies (CAT), who will lead the assessment.
More information: Pre-authorisation - section 2: Steps prior to submitting the application |

Pre-submission meetings |
---|
6 to 7 months before submission of MAA |
Pre-submission meetings are the best opportunity for applicants to obtain procedural and regulatory advice from the Agency:
Marketing authorisation application pre-submission meeting request form
Successful pre-submission meetings along with the information in the guidance should enable applicants to submit applications in line with legal and regulatory requirements. This speeds up the validation process.
More information: Pre-authorisation guidance – section 2: Steps prior to submitting the application
|

Re-confirmation of communicated submission date |
---|
2-3 months before submission of MAA |
Applicants should re-confirm the submission date initially communicated to EMA, or inform EMA of any delays or cancellations, following the guidance below:
If the planned submission date is changed, applicants must inform EMA by re-sending the completed pre-submission request form to pa-bus@ema.europa.eu, selecting 'notification of change' as the scope of the request and stating the new intended submission date in the corresponding field.
Holding successful pre-submission meetings and following this guidance should enable applicants to submit applications in line with legal and regulatory requirements, speeding up the validation process.
More information: Pre-authorisation guidance – section 2: Steps prior to submitting the application
|

Submission and validation of the application |
---|
Applicants should use the electronic common technical document (eCTD) format and submit the application through the eSubmission gateway or web client.
If the Agency needs additional information to complete its validation of the application, it will ask the applicant to supply this by a deadline.
More information:
|

Scientific evaluation |
---|
Up to 210 active days of assessment |
The CHMP evaluates MAA submitted through the centralised procedure. The PRAC provides input on aspects related to risk management and the CAT on advanced therapy medicines.
More information: Pre-authorisation guidance – section 5: Assessment of the application |

CHMP scientific opinion |
---|
After the evaluation, the CHMP must issue a scientific opinion on whether the medicine may be authorised or not.
EMA sends this opinion to the European Commission, which issues the marketing authorisation. The Agency then publishes a summary of the committee's opinion.
More information: Pending European Commission decisions |

European Commission decision |
---|
Within 67 days of receipt of CHMP opinion |
Commission decisions are published in the Community Register of medicinal products for human use and EMA publishes a European public assessment report (EPAR). When a new marketing authorisation application is refused, the Agency publishes a refusal EPAR, including a question and answer document and an assessment report.
More information: What we publish on medicines and when |
How helpful is this page?
Average rating:
Based on 206 ratingsAdd your rating:
- See all ratings
-
23 ratings14 ratings13 ratings27 ratings129 ratings
Related content
Related EU legislation
Related documents
Contact point:
General questions:
Send a question to EMA
Application questions:
Product and application business support
Email: pa-bus@ema.europa.eu